Publications by authors named "V Joo"

Claim this Profile
E
Enrichment of CD7CXCR3 CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma.
R Bartolini, L Trueb, D Daoudlarian, V Joo, A Noto

Ann Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
D Daoudlarian, A Segot, S Latifyan, R Bartolini, V Joo

Ann Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
P-F Petit, D Daoudlarian, S Latifyan, H Bouchaab, N Mederos, V Joo

Ann Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina

Nat Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.
Victor Joo, Constantinos Petrovas, Laurence de Leval, Alessandra Noto, Michel Obeid

Front Immunol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis